ASX - Delayed Quote AUD

Genetic Technologies Limited (GTG.AX)

0.0390

0.0000

(0.00%)

At close: October 16 at 1:07:58 PM GMT+11

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies Limited (Nasdaq:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg ...

ACCESS Newswire 6 months ago

GENE

GNTLF

BIVI
Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2

MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies’ senior leadership who will share insight into the Company’s portfolio of genomic

GlobeNewswire 7 months ago

GENE

GNTLF
Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few year

GlobeNewswire 7 months ago

GENE

GNTLF
Genetic Technologies Full Year 2024 Earnings: AU$0.001 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies ( ASX:GTG ) Full Year 2024 Results Key Financial Results Revenue: AU$9.63m (down 6.9% from FY...

Simply Wall St. 8 months ago

GENE

GNTLF
Genetic Technologies Insider Purchases Yet To Pay Off Regardless Of Recent Strength

Insiders who bought AU$80.3k worth of Genetic Technologies Limited ( ASX:GTG ) stock in the last year have seen some of...

Simply Wall St. 8 months ago

GENE

GNTLF
Genetic Technologies Announces Global Launch of geneType™ on Wholly Owned EasyDNA platform

CHARLOTTE, N.C., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch of the geneType™ Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries, setting the stage for the potential significant expansion of the Company’s current A$7.5m annual reven

GlobeNewswire 8 months ago

GENE

GNTLF
Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on August 15

MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on August 15, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature some of Genetic Technologies Senior Executives, who will share insight into the Company’s portfolio of

GlobeNewswire 8 months ago

GENE

GNTLF
Genetic Technologies Strategic Restructure Driving USA Sales Growth

CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focu

GlobeNewswire 9 months ago

GENE

GNTLF
Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary

MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years’ experience operating across life sciences, technology and consumer segment

GlobeNewswire 9 months ago

GENE

GNTLF
GeneType to Enter Canadian and New Zealand Markets

Genomics-based testing brand expands international presence as pilot influencer campaign fuels salesCHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, today announced the introduction of geneType’s suite of genetic risk assessment tests to Canada and New Zealand. Dovetailing geneType’s recent expansion to the

GlobeNewswire 9 months ago

GENE

GNTLF
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease

Results from commercial sales of predictive testing across the US and Australia establish clear advantages of geneType Risk Assessment Tests for a more preventive approach in disease managementCHARLOTTE, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of pop

GlobeNewswire 10 months ago

GENE

GNTLF
Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27

CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insight into the Company’s

GlobeNewswire 10 months ago

GENE

GNTLF
Genetic Technologies Expands Operational Capacity in North America

Global leader in personalized predictive genetics launches testing operations for geneType disease risk assessments at US based, world-leading genetic laboratory, Gene by GeneCHARLOTTE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, today announces the start of testing operations in the United States for its revolutionary geneType™ genetic risk assess

GlobeNewswire 10 months ago

GENE

GNTLF
GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are excited to announce a major distribution agreement. This partnership will bring GTG's innovative Multi-Risk Test to a broader audience in the online pharmacy channel across North America, empowering individuals to take

GlobeNewswire 10 months ago

GENE

GNTLF
GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer

MELBOURNE, Australia, May 29, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30, assesses a woman’s risk of cancer due to hereditary, inclu

GlobeNewswire 11 months ago

GENE

GNTLF
GeneType and Humanise Health host “Know Your Risk” Event

PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the Know Your Risk event held yesterday at The Langham Pasadena has set a new standard for women’s health initiatives, highlighting the transformative potential of genetic testing and risk assessment. Organized by GeneType and Humanise Health, in partnership wit

GlobeNewswire 11 months ago

GENE

GNTLF

Performance Overview

Return	GTG.AX	S&P/ASX 200 [XJO] (^AXJO)
YTD	--	+0.88%
1-Year	-70.00%	+6.60%
3-Year	-87.00%	+15.60%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Genetic Technologies Limited (GTG.AX)

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2

Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

Genetic Technologies Full Year 2024 Earnings: AU$0.001 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Insider Purchases Yet To Pay Off Regardless Of Recent Strength

Genetic Technologies Announces Global Launch of geneType™ on Wholly Owned EasyDNA platform

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on August 15

Genetic Technologies Strategic Restructure Driving USA Sales Growth

Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary

GeneType to Enter Canadian and New Zealand Markets

GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease

Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27

Genetic Technologies Expands Operational Capacity in North America

GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test

GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer

GeneType and Humanise Health host “Know Your Risk” Event

Performance Overview